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Dear Editor,
Ethionamide (Eto), a structural analogue of 
isoniazid (INH), shares same cellular target 
in fatty acid synthesis, namely inhA.1 It was 
hypothesized that low level of INH resistance 
can induce cross resistance to Eto.2,3 But reports 
explaining the mechanism of cross resistance 
between Eto and INH are limited and are 
still being explored.2,4 The present study was 
aimed at understanding the pattern of Eto 
susceptibility and its association with INH re-
sistance from previously treated patients.
One hundred and seventy-six consecu-
tive Mycobacterium tuberculosis strains iso-
lated from patients failing Category I and II 
included in the study were subjected to drug 
susceptibility testing (DST) for isoniazid and 
ethionamide by minimum inhibitory concen-
tration (MIC) method on Lowenstein-Jensen 
(LJ) medium following the standard proto-
col.5 Pearson chi-square test at 5% level of 
significance using SPSS software version 14.0 was 
performed to assess the significance of association 
between susceptibility pattern of INH and Eto.
Of the 176 isolates, 78% and 22% were re-
sistant and susceptible to INH. Eighty-one 
(49.6%) and 95 (59.3%) isolates showed resistant 
and susceptible phenotype towards Eto. Sixty-
eight (39%) of the 176 isolates were resistant to 
INH and Eto where as 15% (26/176) were sen-
sitive to both drugs. Resistance only to INH or 
Eto was observed in 39% and 7.3% of the isolates 
respectively (Table 1). There is an equal distri-
bution (39%) of Eto susceptible and resistant 
strains among 137 INH resistant isolates. In 
contrast, among the INH susceptible strains, Eto 
susceptible isolates were twice in number than 
resistant isolates. Statistical analysis indicated 
insignificant association (p-value = 0.1) between 
the susceptibility profile of INH and Eto among 
study isolates. 
The presence of high Eto resistance (46%) and 
co-resistance with INH (49.6%) among patients 
under treatment is in accordance with the previ-
ous reports.6-8 It is a known fact that accurate Eto 
susceptibility testing is not possible as there ex-
ists a discrepancy between the testing methods.9 
The breakpoint MIC value for Eto used presently 
was titrated much earlier and there is a chance 
for the shift in breakpoint MIC value in context 
with the current scenario. The MIC obtained for 
INH in the study isolates were ≥ 5 µg/mL indicat-
ing the presence of dominant mutation due to the 
association of katG gene which has no association 
with Eto resistance.2,4 Mechanism for resistance 
to ethionamide has still not been fully deciphered 
and involves more than one gene in develop-
ment of resistance.4 Recently, mechanism based 
on mshA gene indicates a possibility of non-INH 
induced Eto resistance, where insignificant asso-
ciation between susceptibility pattern of INH and 
Eto is expected.10 Hence genetic characterization 
of ethionamide resistance is essential to deter-
mine cross resistance with INH.
To conclude, re-evaluation of breakpoint 
MIC and an accurate test for identifying Eto 
susceptibility profile should be addressed. Cross 
resistance between Eto and INH should be re-
ferred to in context to level of INH resistance. 
The molecular analysis of genes conferring 
resistance to Eto and INH especially the inhA 
gene and its promoter, might explain the role of 
INH in mediating cross resistance towards Eto.
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Table 1. Drug susceptibility pattern of  
Mycobacterium tuberculosis isolates
  Drugs No. of isolates Total
  (%) (%)
 INH Eto  
 R R 68 (39) 
137 (78)
 R S 69 (39) 
 S R 13 (7.3) 
39 (22)
 S S 26 (15) 
 Total 176
R, resistant; S, susceptible; INH, isoniazid; Eto, ethionamide.
Ethionamide resistance from previously treated patients
